Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy

References

• Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009; 45:986 - 90; http://dx.doi.org/10.1016/j.oraloncology.2009.05.635; PMID: 19574086
   PubMed Web of Science ®Google Scholar
• Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, van Herpen CM. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011; 29:e473 - 6; http://dx.doi.org/10.1200/JCO.2010.32.8351; PMID: 21422415
   PubMed Web of Science ®Google Scholar
• Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003; 14:1327 - 8; http://dx.doi.org/10.1093/annonc/mdg331; PMID: 12881399
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, et al, COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983 - 92; http://dx.doi.org/10.1016/S1470-2045(12)70379-0; PMID: 22995653
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138 - 48; http://dx.doi.org/10.1056/NEJMoa1209096; PMID: 23228172
   PubMed Web of Science ®Google Scholar
• Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, Poptani H. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15:986 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-08-1287; PMID: 19188170
   PubMed Web of Science ®Google Scholar
• Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32:2 - 16; http://dx.doi.org/10.1002/jmri.22167; PMID: 20575076
   PubMed Web of Science ®Google Scholar
• Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003; 100:8424 - 9; http://dx.doi.org/10.1073/pnas.1431692100; PMID: 12826609
   PubMed Web of Science ®Google Scholar
• Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, Brasnu D, Laurent-Puig P, Bruneval P, Blons H, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. [Epub ahead of print] Ann Oncol 2013; 24:2624 - 9; http://dx.doi.org/10.1093/annonc/mdt338; PMID: 23933559
   PubMed Web of Science ®Google Scholar
• Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9:1152 - 9; http://dx.doi.org/10.1593/neo.07769; PMID: 18084622
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009; 15:2472 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-08-1763; PMID: 19276248
   PubMed Web of Science ®Google Scholar
• Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 2010; 16:2266 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-09-0238; PMID: 20371674
   PubMed Web of Science ®Google Scholar
• Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem 2011; 11:131 - 49; http://dx.doi.org/10.2174/187152211795495643; PMID: 21603064
   PubMedGoogle Scholar
• Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012; 24:251 - 7; http://dx.doi.org/10.1097/CCO.0b013e32835105b3; PMID: 22327838
   PubMed Web of Science ®Google Scholar
• Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI. PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol 2013; 37:1201 - 7; http://dx.doi.org/10.1097/PAS.0b013e3182880d5a; PMID: 23851329
   PubMed Web of Science ®Google Scholar
• Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12:6643 - 51; http://dx.doi.org/10.1158/1078-0432.CCR-06-1759; PMID: 17121883
   PubMed Web of Science ®Google Scholar
• Licitra L, Perrone F, Bossi P, et al. How High-Risk Human Papillomavirus affects prognosis of patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630 - 6; http://dx.doi.org/10.1200/JCO.2005.04.6136; PMID: 17179101
   PubMed Web of Science ®Google Scholar
• Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009; 11:725 - 36; http://dx.doi.org/10.1215/15228517-2009-003; PMID: 19246520
   PubMed Web of Science ®Google Scholar